Table 4 Univariate analysis for disease-free survival

Whole group

119

50

0.564

-

Age (years)

 < 52

61

22

0.679

0.036

 ≥ 52

58

28

0.435

Curative surgery type

 MRM

80

33

0.562

0.577

 BCS

39

17

0.580

Maximum tumor diameter (cm)

 < 4

65

24

0.630

0.037

 ≥ 4

54

26

0.502

pT stage

 Stages 1 & 2

70

23

0.678

< 0.001

 Stages 3 & 4

49

27

0.407

pN status

 Negative

68

24

0.634

0.023

 Positive

51

26

0.460

Capsular invasion (n = 51)

 Absent

17

6

0.589

0.220

 Present

34

20

0.410

LVI (n = 117)

 Absent

73

26

0.605

0.012

 Present

44

23

0.520

Grade

 II

20

8

0.610

0.627

 III

99

42

0.558

Initial TNM stage

 Stages I & II

71

24

0.659

0.001

 Stage III

47

26

0.414

Pathological subtype

 Spindle cell carcinoma

8

5

0.286

0.032

 Others

111

45

0.582

Pathological subtype

 Squamous cell carcinoma

89

36

0.561

0.853

 Others

30

14

0.584

Ki-67 %

 < 45

58

16

0.736

< 0.001

 ≥ 45

55

34

0.359

Molecular subtype

 TN

77

37

0.501

0.016

 Non-TN

42

13

0.675

NACT receipt

 Not received

78

31

0.632

0.015

 Received

41

19

0.395

NACT type (n = 41)

 Anthracycline/taxanes

27

10

0.474

0.119

 Others

14

9

0.256

Response to NACT (n = 40)

 RCB 0 & I

6

2

NA

0.079

 RCBII & III

34

3

0.725

ACT receipt

 Not received

39

25

0.307

< 0.001

 Received

80

25

0.693

ACT type (n = 80)

 Anthracycline only

20

7

0.820

0.007

 Anthracycline & taxanes

40

10

0.734

 Others

20

9

NA

Start of ACT (days)

 ≤ 30

41

10

0.766

0.186

 > 30

39

15

0.603

PORT

 No

25

13

0.563

0.642

 Yes

94

37

0.564